- Home
- RMCO vs NERV Comparison
RMCO vs NERV Comparison
Compare RMCO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- NERV
- Stock Information
- Founded
- RMCO 2021
- NERV 2007
- Country
- RMCO United States
- NERV United States
- Employees
- RMCO N/A
- NERV N/A
- Industry
- RMCO Multi-Sector Companies
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- NERV Health Care
- Exchange
- RMCO Nasdaq
- NERV Nasdaq
- Market Cap
- RMCO 14.9M
- NERV 12.0M
- IPO Year
- RMCO N/A
- NERV 2014
- Fundamental
- Price
- RMCO $1.48
- NERV $2.00
- Analyst Decision
- RMCO
- NERV Hold
- Analyst Count
- RMCO 0
- NERV 1
- Target Price
- RMCO N/A
- NERV $5.00
- AVG Volume (30 Days)
- RMCO 142.3K
- NERV 16.8K
- Earning Date
- RMCO 08-14-2025
- NERV 08-05-2025
- Dividend Yield
- RMCO 0.34%
- NERV N/A
- EPS Growth
- RMCO N/A
- NERV N/A
- EPS
- RMCO N/A
- NERV 0.83
- Revenue
- RMCO $1,568,212.00
- NERV N/A
- Revenue This Year
- RMCO N/A
- NERV N/A
- Revenue Next Year
- RMCO N/A
- NERV N/A
- P/E Ratio
- RMCO N/A
- NERV $2.35
- Revenue Growth
- RMCO 204.08
- NERV N/A
- 52 Week Low
- RMCO $0.76
- NERV $1.15
- 52 Week High
- RMCO $1.88
- NERV $3.35
- Technical
- Relative Strength Index (RSI)
- RMCO 49.79
- NERV 62.13
- Support Level
- RMCO $1.18
- NERV $1.94
- Resistance Level
- RMCO $1.37
- NERV $2.32
- Average True Range (ATR)
- RMCO 0.17
- NERV 0.14
- MACD
- RMCO -0.02
- NERV 0.03
- Stochastic Oscillator
- RMCO 13.43
- NERV 56.55
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.